Please login to the form below

Not currently logged in
Email:
Password:

neurodegenerative diseases

This page shows the latest neurodegenerative diseases news and features for those working in and with pharma, biotech and healthcare.

Merck & Co signs deal with Amathus for neurodegeneration diseases

Merck & Co signs deal with Amathus for neurodegeneration diseases

Merck &Co has signed a strategic collaboration agreement with Amathus Therapeutics focused on developing novel small molecule candidates for neurodegenerative diseases. ... The Merck neuroscience team is an ideal partner to translate this novel approach

Latest news

More from news
Approximately 3 fully matching, plus 62 partially matching documents found.

Latest Intelligence

  • The search for treatments for Parkinson’s disease The search for treatments for Parkinson’s disease

    and a decade as senior director of neurodegenerative diseases research at Merck Serono where he served as its leader for in vitro pharmacology in neurology, including in multiple sclerosis, Parkinson’s ... and Alzheimer’s diseases.

  • Alzheimer’s: the search for a cure Alzheimer’s: the search for a cure

    big diseases in the field, such as Alzheimer’s, is too limited to make near-term success likely. ... Based on what we felt was the state of the art in terms of understanding the pathogenesis of major diseases, especially neurodegenerative diseases, and

  • A roadmap to the successful treatment of Alzheimer’s disease A roadmap to the successful treatment of Alzheimer’s disease

    Nevertheless, strategies for developing successful therapeutic interventions are shifting. We have developed a five-point roadmap to successful treatments for Alzheimer’s disease and neurodegenerative diseases. ... Hyper-stimulation of microglial cells

  • Brain power: fresh approaches to Alzheimer’s drug discovery Brain power: fresh approaches to Alzheimer’s drug discovery

    The Dementia Consortium provides academic researchers with the funding, industry expertise and project management resources to capitalise on new drug targets for the treatment of the neurodegenerative diseases that cause dementia. ... Diseases include

  • Key considerations for disease- modifying Parkinson’s disease trials Key considerations for disease- modifying Parkinson’s disease trials

    The design of such neuroprotective studies may benefit from the lessons learned in studies in the most common neurodegenerative disease, Alzheimer’s. ... Target early disease stages: It is probably true for all neurodegenerative diseases that symptoms

More from intelligence
Approximately 0 fully matching, plus 13 partially matching documents found.

Latest appointments

More from appointments
Approximately 0 fully matching, plus 12 partially matching documents found.

PMEA Awards 2020

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Windrose Consulting Group

Windrose Consulting Group helps life science companies maximize the commercial value of their products and bring new innovations to market...

Latest intelligence

01 PME-APR21 Cover.jpg
Virtual congresses: video thrilled the cardio tsar
Chris Ross explores the key learnings from a year of virtual congresses...
When Will We Be Back To Normal?
The definitive question of 2021, whether you’re a homeschooling parent, a homebound professional, a wanderer with nowhere to go… or all three at once....
How to tell your healthcare story.
Healthcare research is not a simple story and the people in charge of those moments need to be careful about the story that they tell....

Infographics